In addition, in light of the efficacy showed by SGLT2i and glucagon-like-peptide-1 receptor agonists (GLP1ra) in improving cardiovascular outcomes in patients with T2D and in those with high risk for cardiovascular disease [26], future studies should be conducted to investigate the impact of national and international guidelines on prescription patterns of these therapeutic drug classes in GPs setting. Here, GLP1R is linked to cardiovascular disorder.